EF Hutton has set a course for immune and stuft action with “buy” on Investing.com

On Monday, EF Hutton is reviewing the stock of Imunon (NASDAQ:IMNN), a biotechnology company. The analysts have given a “Buy” rating and set a price of $29.00. Immunon could focus on the development boon IL-12 immunotherapy for the treatment of Eierstock Krebs, the owner of the TheraPlas platform ist.

The TheraPlas platform is a technology, which uses a non-viral, DNA-based plasmid-nanoparticle combination, which is locally influenced. The processing of these products was carried out, a process that is possible as transfection, and then Interleukin-12 (IL-12) will be produced. IL-12 is a Zytokin, which plays a separate role in the immune system, which compensates these stimuli, T-cells and natural killer cells that are recruited, an Abwehr can induce Tumore.

Because EF Hutton has undergone the treatment of immunotherapy, it is possible that the following implicit implications are possible. Because of the therapy that the immune system of the doctors has undergone, it may be more likely that other lenders will get involved.

The analysts are often clinically ill with immunological disorders, lately, IL-12 therapy is one of the best treatments performed now or later or of which no serious disease (UE) has developed. These professional health profiles may involve treatment for the potential treatment and the treatment of clinical treatments.

The Immunon action developed over the years would improve and test the company’s innovative credit treatment. The EF Hutton-Kursziel of 29.00 US-Dollar reflects a positive effect on the Aussichten of the Unternehmens and the potential Auswirkungen seiner IL-12-Immunotherapie on the Treatment of Eierstockkrebs and the possibility to make other Krebsarten wider.

In others, Pharmaunternehmen Imunon, Inc. has established an “At the Market” (ATM) Equity share program, which has undergone a new prospective overnight recovery by the Securities and Exchange Commission. This company is tracking financial sector funding for the second quarter of 2024, a net surplus of $4.8 million and a cash position of $14.5 million after a short-term financing round.

I have received a positive assessment of the date of the Phase II study on Eierstockkrebs and the installation, in 2025 a Phase III study started. If some people are faced with a high degree of regulatory and clinical costs, it is a matter of research. Since the immunity has undergone a Phase I study for a COVID-19 implementation, the immunological dating will take until the end of the years.

CEO Stacy Lindborg outlines Imunon’s Strategy, Partner and Investors for the frozen Phase III trial and other programs for gains. The facility is being decommissioned, during which time an end-of-Phase II meeting with the FDA is being addressed with beans. Development of Imunon, Inc. has come to an end.

InvestingPro Introduction

Where Imunon (NASDAQ:IMNN) is wrong by the likely bet of EF Hutton Aufmerksamkeit, a genauerer View on the financial wealth and market distribution of the foreign investments during InvestingPro-Daten tells a different picture. With a market capitalization of 14.83 million US dollars to an immunological position in the biotech landscape, which is focused on the Wachstum and the intended development, is taught at the innovative IL-12 immunotherapy. The financial knowledge of the external economies was one of the most important revaluations with a negative price-earnings ratio of -0.53, and the profitability of the external economies in a broader mirror was large.

InvestingPro-Tipps have ensured that the economy of the economy was quickly financed, which made the financing of the financing of Forschung and Entwicklung possible. The cooperation with the external parties is for a higher price development possible, but it was the best way to create a higher risk profile that can lead to a higher risk profile. Analysts who have not valued InvestingPro, while Immunon would be profitable in these years, the spectacular nature of investments in the biotech sector was not interesting.

If the company has executed a transaction in the 30 days of the 18% inheritance, the meaning was one of the intended investments in the pursuit of this investment. For those years, part of the financing and market analyses of imuninteresting is, because InvestingPro also gives tips, which get other orientations.

It is important that these financial resources provide the opportunity to erase the immunotherapy IL-12-Immunotherapy during the course of treatment. The strategic approach to internal economies is based on the business of eierstockkrebs and other credit institutions that can undertake a long-term development in the oncology industry and the acquisition of activities. For a full list of InvestingPro Tips and an umfassende Analysis, visit https://de.investing.com/pro/IMNN.

This description can be performed by the intelligent intelligence. Weitere Informationen entnehmen Sie bitte unseren Nutzungsbedingungen.